

# Current Lung-MAP Schema

## Biomarker-Driven Sub-Studies

## Non-Match Sub-Studies

Completed 12/12/16  
Completed 09/01/16  
Completed 10/31/16  
Closed 11/25/14

**S1400B**  
PI3K+

**S1400C**  
CCGA+\*

**S1400D**  
FGFR+

**S1400E**  
c-Met

**S1400G**  
HRRD+\*

Upcoming

**S1400K**  
c-Met+

Completed 12/18/15

**S1400A**  
Non-match

**S1400I**  
Checkpoint Naive

**S1400F**  
Checkpoint Refractory

Taselisib

Palbociclib

AZD4547

Rilotumumab  
/Erlotinib

Erlotinib

Talazoparib

Telisotuzumab  
Vedotin

Durvalumab

Nivolumab/  
Ipilimumab

Nivolumab

Durvalumab/  
Tremelimumab

400 km

300 Miles

# Future Re-Design

Previously-treated Stage IV or Recurrent  
Non-Small Cell Lung Cancer  
**(All Histology)**  
Immunotherapy or Chemotherapy Relapsed/Refractory Patients

**Biomarker-Driven Sub-Studies**

**Non-Match Sub-Studies**

**Biomarker 1 Positive**

**Biomarker n Positive**

**IO Naïve (Squamous O-only)**

**IO Relapsed/Refractory**

**Sub-study 1 Biomarker-driven Therapy**

**Sub-study n Biomarker-Driven Therapy**

**Nivolumab + Ipilimumab vs Nivolumab**

**Collect Tissue for Immuno Biomarker Profiling**

**Investigational Therapy 1**

**Investigational Therapy n**

**S1400I**

**Randomization**

**Investigational Therapy 1**

**Standard of Care**


**Investigational Therapy n**

**Standard of Care**

**IO Sub-Study 1 IO Combo 1**

**IO Sub-Study m IO Combo m**

**Common Control Dealer's Choice Based on Histology**





## Real Change, Real Benefits

- **Enrollment Efficiency:** Grouping these studies under a single trial reduces the overall failure rate for patient biomarker screening
- **Operational Efficiency:** Single master protocol can be amended as needed as drugs enter and exit the study
- **Consistency:** Every drug entered into the trial will be tested in the identical manner
- **Predictability:** If pre-specified efficacy and safety criteria are met, the drug and accompanying companion diagnostic will be approved
- **Patient Benefit:** Brings safe and effective drugs to patients sooner than they might otherwise be available.